First Author: E.Mensah -0
Co Author(s): E. Papamichael M. Ting E. Mensah 0 0 0 0 0 0 0 0 0
Back to previous
Ozurdex is a treatment for macular oedema secondary to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). This review was designed to assess the efficacy and safety of Ozurdex injections in patients with macular oedema secondary to either CRVO or BRVO.
This prospective study took place in a district general hospital over the course of 6 months. Patients included in the study were diagnosed with either a CRVO or BRVO and may, or may not, have previously received macula laser and/or anti-VEGF therapy
15 patients were reviewed on the day of receiving their Ozurdex implant as well as at each consecutive monthly visit thereafter for 6 months. The following parameters were recorded: visual acuity (VA), central macular thickness (CMT), time to reinjection and complication rate.
6/15 (40%) patients had CRVO, 9/15 (60%) had BRVO, 7/15 (46.7%) received previous macula laser and 5/15 (33.3%) received previous anti-VEGF therapy. VA improved by ≥10 letters in 7/15 (46.7%) and ≥15 letters in 5/15 (33.3%). Mean highest VA was recorded at 2.0 months. 8/15 (53.5%) demonstrated VA above baseline at 6 months. All patients had reduced CMT within 1 week following injection. Mean lowest CMT was recorded at 2.4 months. 13/15 (86.7%) patients demonstrated CMT below baseline at 6 months. Raised intraocular pressure (defined as ≥25mmHg) occurred in 3/15 (20%) patients between months 1 – 3, requiring topical medication alone. No cases of endophthalmitis occurred. 7/15 (46.7%) patients received a second injection at 5.9 months (average).
In a district general hospital setting, CMT was shown to improve faster than VA, however, the average time to greatest improvement was similar for both. We propose that retreatment with Ozurdex be considered on an individual basis from 4 months post-injection once steroid-responding status has been confirmed.